Inestabilidad de placas plegadas prismáticas. Por el método de bandas finitas

El método de bandas finitas se emplea para determinar cargas de bifurcación de láminas plegadas prismáticas apoyadas en diafragmas en sus extremos. La formulación de estabilidad es de tipo energético y permite tratar tanto cargas sólidas como líquidas, incluyendo la influencia del movimiento de un líquido en modos de inestabilidad torsional. Se presentan ejemplos numéricos para evaluar convergencia de la solución y aplicaciones a problemas de inestabilidad torsional de vigas de pared delgada. Estudios paramétricos realizados sobre un ejemplo permiten comparar distintas formas de sección transversal en su comportamiento en pandeo.Peer Reviewe

Bulk Mediated Surface Diffusion: The Infinite System Case

An analytical soluble model based on a Continuous Time Random Walk (CTRW) scheme for the adsorption-desorption processes at interfaces, called bulk-mediated surface diffusion, is presented. The time evolution of the effective probability distribution width on the surface is calculated and analyzed within an anomalous diffusion framework. The asymptotic behavior for large times shows a sub-diffusive regime for the effective surface diffusion but, depending on the observed range of time, other regimes may be obtained. Montecarlo simulations show excellent agreement with analytical results. As an important byproduct of the indicated approach, we present the evaluation of the time for the first visit to the surface.Comment: 15 pages, 7 figure

Bulk Mediated Surface Diffusion: Finite System Case

We address the dynamics of adsorbed molecules (a fundamental issue in surface physics) within the framework of a Master Equation scheme, and study the diffusion of particles in a finite cubic lattice whose boundaries are at the $z=1$ and the $z=L$ planes where $L = 2,3,4,...$, while the $x$ and $y$ directions are unbounded. As we are interested in the effective diffusion process at the interface $z = 1$, we calculate analytically the conditional probability for finding the system on the $z=1$ plane as well as the surface dispersion as a function of time and compare these results with Monte Carlo simulations finding an excellent agreement.Comment: 19 pages, 8 figure

The OI Line Emission in Active Galactic Nuclei Revisited

UV, visible, and near-infrared spectroscopy is used to study the transitions of neutral oxygen leading to the emission of broad OI $\lambda$8446, $\lambda$11287 and $\lambda$1304 in Active Galactic Nuclei. From the strength of the former two lines, contrary to the general belief, we found that in six out of seven galaxies, L-beta fluorescence is not the only mechanism responsible for the formation of these three lines. Because OI $\lambda$13165 is almost reduced to noise level, continuum fluorescence is ruled out as an additional excitation mechanism, but the presence of OI $\lambda$7774 in one of the objects suggests that collisional ionization may have an important role in the formation of OI $\lambda$8446. The usefulness of the OI lines as a reliable reddening indicator for the broad line region is discussed. The values of E(B-V) derived from the OI $\lambda 1304/\lambda$8446 ratio agree with those obtained using other reddening indicators. The observations point toward a break in the one-to-one photon relation between OI $\lambda$8446 and OI $\lambda$1304, attributable to several destruction mechanisms that may affect the latter line.Comment: 26 pages, 5 figures. Accepted for publication in Ap

Mieloptisis y Síndrome de Kasabach Merrit como manifestación inicial de angiosarcoma esplénico

El angiosarcoma primario de bazo es una enfermedad maligna, inusual y agresiva. La invasión de la medula ósea y las alteraciones en la coagulación han sido descriptos de forma aislada. Presentamos una paciente de 26 años, que consultó por dolor abdominal, y en estudios iniciales anemia severa y trombocitopenia, asociada a la presencia de reacción leucoeritroblástica. Se observaron también signos de coagulopatía por consumo y microangiopatía: esquistocitos, tiempo de protrombina prolongado, fibrinógeno disminuido y dímero D aumentado. Los estudios imagenológicos demostraron hepatoesplenomegalia con  lesiones nodulares de diferentes densidades en ambos órganos, además de nodulillos pulmonares y lesiones óseas con neovascularización. El cuadro clínico de Síndrome de Kasabach Merrit y la presencia de tumor vascular llevó a la sospecha de tumor esplénico primario. Se realizó esplenectomía y biopsia de medula ósea, logrando así, el diagnóstico de angiosarcoma primario de bazo en estadio metástasico.  </p

Diastereoselective Synthesis of C60/Steroid Conjugates

The design and synthesis of fullerene–steroid hybrids by using Prato’s protocol has afforded new fullerene derivatives endowed with epiandrosterone, an important naturally occurring steroid hormone. Since the formation of the pyrrolidine ring resulting from the 1,3-dipolar cyloaddition reaction takes place with generation of a new stereogenic center on the C2 of the five-membered ring, the reaction proceeds with formation of a diastereomeric mixture [compounds 6 and 7 in 70:30 ratio, 8 and 9 in 26:74 ratio (HPLC)] in which the formation of the major diasteroisomers 6 and 9 is consistent with an electrophilic attack of [60]fullerene on the Re face of the azomethine ylide directed by the steroidic unit. The chiroptical properties of these conjugates reveal typical Cotton effects in CD spectra that have been used to assign the absolute configuration of the new fulleropyrrolidines. The electrochemical study of the new compounds reveals the presence of four quasi-reversible reduction waves which are cathodically shifted in comparison with the parent C60, thus ascertaining the proposed structures.Financial support by the Ministerio de Ciencia e Innovación (MINECO) of Spain (CTQ2011-24652, CTQ2011-27253, PIB2010JP-00196, and CSD2007-00010 projects) and CAM (Madrisolar-2) is acknowledged; A.R. thanks UCM for financial support; M.S. is indebted to Programa del Grupo Santander 2012

Procesos de Oxidación avanzada en el tratamiento de agua

A lo largo de este libro diversos autores especializados exponen el tema permitiendo al lector encontrar desde principios básicos, hasta aplicaciones de procesos, resultando ser una fuente de consulta con una visión amplia de los procesos de oxidación avanzada y sus aplicaciones dentro del tratamiento de agua.El agua es un líquido vital, sin ella no podemos subsistir. Además de usarla en nuestro hogar, se utiliza en gran variedad de procesos industriales para la transformación de materias primas en productos terminados. El agua usada industrialmente cambia su composición fisicoquímica, ya que agregamos un sinfín de compuestos orgánicos e inorgánicos. Por ello, es necesario desarrollar nuevas metodologías que permitan de manera segura y eficiente recuperar la calidad del agua usada originalmente para poder usarla.Universidad Autónoma del Estado de Méxic

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p&lt;0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (&lt;1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (&lt;1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline